Imugene Limited
![star rating](/static/images/star.png?v=1.02)
Tuesday: 09:00 - 17:00
Wednesday: 09:00 - 17:00
Thursday: 09:00 - 17:00
Friday: 09:00 - 17:00
Saturday: -
Sunday: -
About Imugene Limited
Imugene is a publicly-listed biotech company with operations in America and Europe, developing cancer immunotherapies targeting B-cell peptide vaccines.
Imugene Limited Description
Imugene (ASX; IMU) is an oncology focused biopharmaceutical company developing clinical immunotherapeutics to advance cancer care. The Company’s lead product is HER-Vaxx, a proprietary immunotherapeutic vaccine that stimulates a polyclonal antibody response to HER-2 /neu. HER-2 /neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer. Imugene’s corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria. For more information on Imugene, please visit www. imugene.com
More about Imugene Limited
Tuesday: 09:00 - 17:00
Wednesday: 09:00 - 17:00
Thursday: 09:00 - 17:00
Friday: 09:00 - 17:00
Saturday: -
Sunday: -